PMID- 28381321
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 2152-6575 (Print)
IS  - 2152-6567 (Electronic)
IS  - 2152-6567 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Mar 1
TI  - The impact of total immunoglobulin E levels on outcomes of maximal medical 
      therapy for chronic rhinosinusitis.
PG  - 5-12
LID - 10.2500/ar.2017.8.0188 [doi]
AB  - INTRODUCTION: The goal of this project was to evaluate the impact of 
      immunoglobulin E (IgE) levels on outcomes in patients with chronic rhinosinusitis 
      (CRS) who received maximal medical therapy (MMT). STUDY DESIGN: Prospective 
      cohort study. METHODS: Thirty-eight patients who underwent MMT for CRS were 
      assigned to three different cohorts based on their IgE levels: low IgE (<25 IU), 
      moderate (>25 to <149 IU), and high (>/=150 IU). The primary outcome evaluated was 
      MMT failure with a surgical recommendation within each IgE cohort. Secondary 
      outcomes included changes in pre- and post-MMT scores for the Rhinosinusitis 
      Disability Index, Chronic Sinusitis Survey, and computed tomography-based 
      Lund-Mackay evaluation. The cohorts were substratified based on the presence of 
      nasal polyps and nasal allergies. RESULTS: No significant difference was found 
      when MMT failure was compared between the cohorts in terms of quality of life. 
      When substratified based on the presence of nasal polyps and nasal allergies, 
      there was no significant difference between the cohorts. In the high-IgE cohort, 
      all patients regardless of presence of nasal polyps and nasal allergic disease, 
      frequently failed MMT and were recommended for surgery. CONCLUSIONS: Overall, IgE 
      levels did not seem to have a significant effect on the quality of life or 
      outcomes of MMT in the patients with CRS. However, the presence of nasal 
      allergies regardless of IgE levels seemed to result in more frequent 
      recommendations for surgery after MMT. In the patients with higher-IgE levels 
      (>/=150 IU), MMT seemed to fail at high rates with or without the presence of 
      polyps or allergic disease.
FAU - Lemos-Rodriguez, Ana M
AU  - Lemos-Rodriguez AM
FAU - Farzal, Zainab
AU  - Farzal Z
FAU - Sreenath, Satyan B
AU  - Sreenath SB
FAU - Thorp, Brian D
AU  - Thorp BD
FAU - Senior, Brent A
AU  - Senior BA
FAU - Zanation, Adam M
AU  - Zanation AM
FAU - Ebert, Charles S Jr
AU  - Ebert CS Jr
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Allergy Rhinol (Providence)
JT  - Allergy & rhinology (Providence, R.I.)
JID - 101570968
PMC - PMC5380453
COIS- The authors have no conflicts of interest to declare pertaining to this article
EDAT- 2017/04/07 06:00
MHDA- 2017/04/07 06:01
PMCR- 2017/03/01
CRDT- 2017/04/07 06:00
PHST- 2017/04/07 06:00 [entrez]
PHST- 2017/04/07 06:00 [pubmed]
PHST- 2017/04/07 06:01 [medline]
PHST- 2017/03/01 00:00 [pmc-release]
AID - AR056-16 [pii]
AID - 10.2500/ar.2017.8.0188 [doi]
PST - ppublish
SO  - Allergy Rhinol (Providence). 2017 Mar 1;8(1):5-12. doi: 10.2500/ar.2017.8.0188.